HOME >> MEDICINE >> NEWS
Preclinical results of Geovax's AIDS vaccines demonstrate potential to protect against disease

GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company, today reported successful results from a preclinical trial using GeoVax's vaccines for the therapeutic treatment and prevention of Acquired Immunodeficiency Disease Syndrome ("AIDS") in non-human primates. The data demonstrate the effectiveness of GeoVax's DNA/MVA vaccines in controlling the Simian ("SIV") AIDS virus through immune responses raised by the vaccines. These promising results have resulted in preliminary plans to conduct human therapeutic studies utilizing GeoVax's vaccines.

In this trial, two monkeys were infected with the SIV AIDS virus and then placed on drug therapy. Thereafter, once early drug therapy had temporarily reduced virus levels, the monkeys were vaccinated with the SIV version of GeoVax's DNA/MVA vaccines. Six weeks after vaccination, drug treatment was discontinued. The SIV virus levels temporarily rose in the vaccinated individuals, but were later "controlled" (reduced to much lower levels) by immune responses raised by the vaccines.

The reduction of virus levels in the blood stream of these AIDS virus-infected non-human primates has continued for more than a year to date. Vaccination with the GeoVax DNA/MVA vaccines has curtailed the development of AIDS and its associated debilitating effects, resulting in healthy, asymptomatic individuals. The monkeys have gained weight and have not required any additional drug therapy.

"The results of this trial demonstrate the long-term promise of our vaccines in treating HIV-AIDS," said Don Hildebrand, CEO of GeoVax Labs. "Our preclinical trials, coupled with encouraging data from two ongoing human trials, help validate the science behind our vaccines and provide the impetus for accelerating the planning of Phase II human trials for our preventive vaccines."

The ability to vaccinate those already infected with the AIDS virus, thereby inhibiting the virus' progressive and de
'"/>

Contact: Melanie Nimrodi
mnimrodi@mww.com
312-546-3508
Financial Relations Board
6-Feb-2007


Page: 1 2

Related medicine news :

1. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
2. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
3. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
4. Targeted, oral agent Enzastaurin shows favorable results
5. Childhood obesity intervention shows promising results
6. Alpharma presents positive pharmacokinetic study results
7. UCSF brain tumor vaccine trial shows promising results
8. The eyes have it -- Autism research yields surprising results
9. ACP: Residency match results for internal medicine underscore need to redesign primary care
10. Positive results more likely from industry-funded breast cancer trials
11. Leading advocates express support for microbicide research, despite disappointing trial results

Post Your Comments:
(Date:7/28/2015)... ... 2015 , ... BiologicsMD, Inc. , a privately held ... of bone disorders and conditions of hair loss, announced that the U.S. Patent ... Binding-Domain and Parathyroid Hormone". The issued patent claims methods of use for promoting ...
(Date:7/28/2015)... ... July 28, 2015 , ... ... include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... It provides physicians who are anticipating making a subspecialty referral an efficient ...
(Date:7/28/2015)... ... July 28, 2015 , ... Every summer, the public is reminded to leave ... lighting fireworks in their own neighborhoods. Unfortunately, according to a recent report issued by ... USA Today article " Eye Injuries Caused by Fireworks Doubled in Last 3 Years ...
(Date:7/28/2015)... CA (PRWEB) , ... July 28, 2015 , ... ... of Acute Coronary Syndromes (ACS-Heart Attack, Sudden Death, or Angina), many of whom ... cardiology is the identification of individuals with active yet undetected sub-clinical disease, who ...
(Date:7/28/2015)... ... July 28, 2015 , ... There has been much discussion in ... bridges and railroads, often overlooked is the over 740,000 miles of municipal sewer ... into sewage treatment facilities. According to the American Society of Civil Engineers , ...
Breaking Medicine News(10 mins):Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 2Health News:Carlsbad Ophthalmologist Discusses Doubling of Fireworks Eye Injuries in Three Year Span 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 2Health News:With an Infrastructure Spending Bill on the Horizon, RestorationEze Discusses the Impact an Aging Sewer System is Having on Homeowners 3
(Date:7/28/2015)...  Today, Sekisui Diagnostics announces the launch of the ... with a broad menu of high quality SEKURE reagents, ... office or hospital laboratory. The SK500 ... ISE, 72 patient sample on-board capability, minimizes the use ... ISE) to meet the testing needs of small-to-moderate volume ...
(Date:7/28/2015)... Voalte, the leader in healthcare communication ... wireless communications, today announced that Bay Area Regional ... facility in Webster, Texas , ... on Spectralink PIVOT™ purpose-built smartphones for caregiver communication.  ... member of its AIMS Partner Program last fall, ...
(Date:7/28/2015)... 28, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... underwritten public offering of 6,666,667 shares of its ... $11.25 per share. The gross proceeds to Egalet ... $75 million, before deducting the underwriting discounts and ...
Breaking Medicine Technology:Sekisui Diagnostics Announces Launch of SK500 Clinical Chemistry System for US Laboratories 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3Egalet Announces Pricing of Public Offering of Common Stock 2Egalet Announces Pricing of Public Offering of Common Stock 3Egalet Announces Pricing of Public Offering of Common Stock 4
Cached News: